微超声在前列腺癌筛查中的价值:一项回顾性真实世界可行性研究
该研究回顾性分析682例接受微超声(MUS)和PSA检测的男性,采用PSA密度(PSAD)修正的阴性MUS标准进行风险分层。结果显示PSAD修正的PRI-MUS评分对临床显著前列腺癌(csPCa)的敏感性为83.3%、特异性为59.1%、阴性预测值89.7%,可减少过度诊断和阴性活检。
要点
- PSAD修正的PRI-MUS评分对csPCa敏感性83.3%、特异性59.1%。
- PSAD修正阴性MUS可避免13例阴性活检,漏诊2例csPCa。
- 相比MRI路径,PSAD修正阴性MUS可减少17例(24.7%)因阴性活检而做的MRI,漏诊0例csPCa。
核心结论
- MUS结合PSAD可在机会性筛查中有效进行前列腺癌风险分层,支持前瞻性试验开展。
研究设计与样本
- 回顾性分析682例连续接受MUS和PSA检测的男性,根据指南建议进行活检和MRI。
- PSAD修正阴性MUS定义为PRI-MUS 1、2或3且PSAD<0.15 ng/mL²;阳性定义为PRI-MUS 3且PSAD≥0.15 ng/mL²、4或5。
主要发现
- 中位年龄59岁,中位PSA 1.2 ng/mL(IQR 0.6-3.5)。
- 62例接受活检,检出PCa 29例(47%),其中csPCa 18例(29%)。
- 88例(13%)为PSAD修正阳性MUS,检出15例csPCa和7例ncsPCa;594例(87%)为阴性MUS,检出3例csPCa和4例ncsPCa。
- 相比PSA≥3 ng/mL活检指征,PSAD修正阴性MUS可避免13例阴性活检,漏诊2例csPCa和4例ncsPCa。
- 相比MRI指征(PI-RADS≥3,n=38),PSAD修正阴性MUS(n=594)可避免3例阴性活检和17例(占69例的24.7%)因阴性活检而做的MRI,漏诊0例csPCa。
关键数值与推荐
- PSAD修正阴性MUS:PRI-MUS 1、2或3且PSAD<0.15 ng/mL²;阳性:PRI-MUS 3且PSAD≥0.15 ng/mL²、4或5。
- PSA基于活检指征为≥3 ng/mL;MRI基于活检指征为PI-RADS≥3。
临床怎么用
- 在机会性筛查中,可采用PSAD修正的PRI-MUS评分进行风险分层,以减少不必要的活检和MRI。
- PSAD修正阴性MUS的阴性预测值较高(89.7%),但仍需注意漏诊csPCa的风险。
局限性
- 回顾性真实世界研究设计,结果需前瞻性试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Prostate cancer (PCa) screening is increasingly guided by imaging. High-resolution 29 MHz Micro-Ultrasound (MUS) offers a promising alternative to magnetic resonance imaging (MRI). METHODS: We retrospectively analyzed 682 consecutive men undergoing MUS and PSA testing during routine examination. Biopsy and MRI were performed according to guideline recommendations. PSA density (PSAD)-modified negative MUS included PRI-MUS categories 1, 2, or 3 with PSAD < 0.15 ng/mL2; PSAD-modified positive MUS included PRI-MUS categories 3 with PSAD ≥ 0.15 ng/mL2, 4 or 5. RESULTS: Median age was 59 years; median PSA 1.2 ng/mL (IQR: 0.6-3.5). Biopsies were performed in 62 men, detecting PCa in 29 (47%), including 18 (29%) clinically significant PCa (csPCa). 88 men (13%) had PSAD-modified positive MUS, yielding 15 csPCa and 7 non-clinically significant PCa (ncsPCa). Among 594 men (87%) with PSAD-modified negative MUS, 3 csPCa and 4 ncsPCa were detected. Compared to PSA-based biopsy indication ≥3 ng/mL, PSAD-modified negative MUS would have avoided 13 negative, missing two csPCa and four ncsPCa. Compared to the MRI-based biopsy indication (PI-RADS ≥ 3, n = 38), PSAD-modified negative MUS (n = 594) would have spared 3 negative biopsies, as well as 17 (24.7% of 69) MRIs due to negative biopsy, while missing 0 cases of csPCa. Additionally, MRI could have been omitted in 1csPCa case and 9 ncsPCa cases with positive MUS, and in 13 csPCa and 7 ncsPCa cases based on PSAD-modified positive MUS. The PSAD-modified-PRI-MUS-based screening pathway showed a 6.29-fold (OR = 0.16) reduction in overdiagnosis and 7.22-fold (OR = 0.14) reduction in negative biopsies/ncsPCa. MUS without PSA demonstrated an OR of 7.30 to detect csPCa. PSAD-modified-PRI-MUS score demonstrated a sensitivity of 83.3%, a specificity of 59.1%, a positive predictive value of 45.5% and a negative predictive value of 89.7% for distinguishing csPCa from benign/ncsPCa findings. CONCLUSION: MUS enables effective PCa risk stratification in an opportunistic screening setting supporting prospective trial development. TRIAL REGISTRATION: This study is part of the PROSTAMUS trial, registered in the DRKS/WHO registry.
引用
- Wendler JJ, Bechstein J, Buckendahl J, et al. The value of micro-ultrasound for prostate cancer screening: A retrospective real-world feasibility study. Prostate Cancer Prostatic Dis. 2026. PMID: 41588191. doi:10.1038/s41391-026-01075-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。